GNA & Boehringer collaborate on ASF diagnostic test development
Category: #health  By Pankaj Singh  Date: 2019-02-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

GNA & Boehringer collaborate on ASF diagnostic test development
  • Both the companies will come up with holistic solutions for farmers, veterinarians, and the food producing industry.
  • The partnership aims to develop a diagnostic test for ASF.

Research-driven pharma conglomerate Boehringer Ingelheim has joined forces with GNA Biosolutions, in a bid to accelerate the development of a rapid ASF (African swine fever) diagnostic test. If reports are to be believed, the test that would be developed via the research partnership between Boehringer and the German molecular technology company will be used in consort with the latters portable molecular diagnostic platform and will aim to support the fight against the spread of this disease worldwide.

Speaking on the partnership, Rolf-Dieter Günther, Global Head, Diagnostics & Monitoring Animal Health, Boehringer Ingelheim, stated that in partnership with GNA, the company aims to come up with holistic solutions for farmers, veterinarians, and the food producing industry as a whole. The targeted platform will be designed to enable quicker decision-making based on the availability of highly comprehensive diagnostic data, Rolf-Dieter Günther further asserted.

For the uninitiated, ASF is a highly fatal swine infection that leads to severe clinical diseases. There is no current treatment for ASF, and no effective vaccines are available either. It has been reported that the massive outbreaks of ASF across Vietnam and China have been negatively impacting pork prices and demand since quite a while. As per a press release by Boehringer Ingelheim, ASF outbreaks led to more than 600,000 pigs culled in China alone, since the last few months.

Lars Ullerich, Managing Director & Co-founder, GNA Biosolutions, stated that this partnership stresses on the role that the company plays in the robustly expanding extra-laboratory diagnostics industry and also extends the application scope of GNA’s Pulse Controlled Amplification technology into animal protection.

As per reliable sources, neither GNA Biosolutions nor Boehringer Ingelheim have revealed any financial information pertaining to the said agreement so far.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Dressbarn confirms 53 stores to close in August as wind down nears
Dressbarn confirms 53 stores to close in August as wind down nears
By Pankaj Singh

Ascena shares have been down by more than 75% this year and are trading at below $1 Ascena Retail Group, an American retailer for women’s clothing, recently announced that it is going to shut down 53 locations of Dressbarn by the end of August...

Japan introduces working group to examine impact of Facebook’s Libra
Japan introduces working group to examine impact of Facebook’s Libra
By Pankaj Singh

Japan is looking to garner greater support due to the wide range of policies which can be affected by digital currencies. Japanese authorities have reportedly established a working group to discuss the impact Libra digital coin proposed by Facebook ...

Ligand Pharma announces positive results from trial of CE-Iohexol
Ligand Pharma announces positive results from trial of CE-Iohexol
By Pankaj Singh

Ligand Pharmaceuticals, a US-based biopharmaceutical company recently announced positive top line results from clinical trial of its internal CE (Captisol-enabled) Iohexol program. The study attained primary endpoint indicating pharmacokinetic b...